A team of scientists at Yale University has developed a new form of “airborne” mRNA vaccine that can be rapidly deployed among the public to vaccinate the masses without their knowledge or consent.
The researchers developed the new airborne method to deliver mRNA right into people’s lungs, bypassing the need for voluntary injections.
The method has also been used to vaccinate mice intranasally.
The scientists note that animal tests have now “opened the door for human testing in the near future.”
While scientists may celebrate this invention as a convenient method to vaccinate large populations, critics are raising obvious concerns about the potential misuse of an airborne vaccine.
The method raises serious concerns about the possibility of covert bio-enhancements – a concept that has previously been suggested in academic literature.
Roman Balmakov raises the alarm about the new “Air Vax” during an episode of the Epoch Times show “Facts Matter.”
In research conducted on mice, Yale University scientists developed polymer nanoparticles to encapsulate mRNA.
This method transforms mRNA into an inhalable form for delivery to the lungs.
The study was recently highlighted in the Science Translational Medicine publication.
Science Translational Medicine‘s editor Courtney Malo explains that the airborne vaccines can be used to vaccinate the public for Covid without relying on injections.
“The ability to efficiently deliver mRNA to the lung would have applications for vaccine development, gene therapy, and more,” Malo said.
“Here, Suberi et al. showed that such mRNA delivery can be accomplished by encapsulating mRNAs of interest within optimized poly(amine-co-ester) polyplexes [nanoparticles].
“Polyplex-delivered mRNAs were efficiently translated into protein in the lungs of mice with limited evidence of toxicity.
“This platform was successfully applied as an intranasal SARS-CoV-2 vaccine, eliciting robust immune responses that conferred protection against subsequent viral challenge.
“These results highlight the potential of this delivery system for vaccine applications and beyond.”
The team of Yale scientists was led by cellular and molecular physiologist Mark Saltzman.
Saltzman claims that the inhalable mRNA vaccine “successfully protected against SARS-CoV-2,” and that it “opens the door to delivering other messenger RNA (mRNA) therapeutics for gene replacement therapy and other treatments in the lungs.”
For the study, mice received two intranasal doses of nanoparticles carrying mRNA COVID-19 vaccines.
The vaccines proved to be effective in the animals after delivering mRNA into their lungs.
Previously, lung-targeted mRNA therapies struggled to make it into the cells necessary to express the encoded protein, known as poor transfection efficiency.
“The Saltzman group got around this hurdle in part by using a nanoparticle made from poly(amine-co-ester) polyplexes, or PACE, a biocompatible and highly customizable polymer,” a Yale University news release explains.
In a previous study, Saltzman had tried a “prime and spike” system to deliver COVID-19 shots.
The method involved injecting mRNA shots into a muscle before spraying spike proteins into the nose.
However, after fruether experiments, scientists realized that the injection portion may be unnecessary.
Saltzman says he now has high hopes for the airborne delivery method, beyond vaccines:
“In the new report, there is no intramuscular injection.
“We just gave two doses, a prime, and a boost, intranasally, and we got a highly protective immune response.
“But we also showed that, generally, you can deliver different kinds of mRNA. So it’s not just good for a vaccine, but potentially also good for gene replacement therapy in diseases like cystic fibrosis and gene editing.
“We used a vaccine example to show that it works, but it opens the door to doing all these other kinds of interventions.”
The team of scientists believes their new “Air Vax” could “radically change” how people are vaccinated by circumventing unpopular injections.
Saltzman says this “new method of delivery could radically change the way people are vaccinated.”
He claims that the system will make it easier to vaccinate people in remote areas.
The scientist also boasts that the “Air Vax” can be used to vaccinate people who are afraid of needles.
An airborne vaccine also makes it possible to rapidly disseminate it across a population, Saltzman notes.
By releasing the vaccine in the air, there’s no need to inject each person individually.
Rolling out vaccines that require injections is not only time-consuming and expensive but also difficult if an individual objects to the shot.
This isn’t the case with an airborne vaccine, however.
The “Air Vax” can be released into the air without the public’s consent or even people’s knowledge.
A similar strategy is being used with mRNA in shrimp, which are too small and numerous to be injected individually.
Instead, an oral “nano vaccine” was created to stop the spread of a virus.
Shai Ufaz, the CEO of ViAqua, which developed the technology, stated:
“Oral delivery is the holy grail of aquaculture health development due to both the impossibility of vaccinating individual shrimp and its ability to substantially bring down the operational costs of disease management while improving outcomes …”
While the Yale scientists are targeting an intranasal mRNA product, the outcome is the same.
The objective is to get as many people exposed as possible with the least amount of cost and effort.
According to the Yale study:
“An inhalable platform for messenger RNA (mRNA) therapeutics would enable minimally invasive and lung-targeted delivery for a host of pulmonary diseases.
“Development of lung-targeted mRNA therapeutics has been limited by poor transfection efficiency and risk of vehicle-induced pathology.
“Here, we report an inhalable polymer-based vehicle for the delivery of therapeutic mRNAs to the lung.
“We optimized biodegradable poly(amine-co-ester) (PACE) polyplexes [nanoparticles] for mRNA delivery using end-group modifications and polyethylene glycol.
“These polyplexes achieved high transfection of mRNA throughout the lung, particularly in epithelial and antigen-presenting cells.
“We applied this technology to develop a mucosal vaccine for severe acute respiratory syndrome coronavirus 2 and found that intranasal vaccination with spike protein–encoding mRNA polyplexes induced potent cellular and humoral adaptive immunity and protected susceptible mice from lethal viral challenge.
“Together, these results demonstrate the translational potential of PACE polyplexes for therapeutic delivery of mRNA to the lungs.”